News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Takeda Pharmaceutical Co. Ltd. (TKPYY) And Zinfandel Pharmaceuticals Inc. To Present Data At Upcoming Alzheimer's Association International Conference® Highlighting Innovative Approaches To Alzheimer's Disease Research And Development


7/10/2014 10:43:47 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OSAKA, Japan and DURHAM, N.C., July 10, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), will present data during multiple poster and oral sessions at the upcoming Alzheimer's Association International Conference® 2014 (AAIC®), taking place in Copenhagen, Denmark from July 12-17, 2014.

"Studies show that individuals with mild cognitive impairmenta slight, although noticeable and measurable decline in cognitive abilitiesare at an increased risk of developing Alzheimer's disease or another dementia. An option to be able to predict an individual's risk for developing this disease would be welcomed by the medical community," said Stephen Brannan, M.D., Central Nervous System Development Therapeutic Area Head, Takeda. "Therefore, a special focus for Takeda at this conference will be presenting updates on the TOMMORROW Triala trial that challenges the status quo and aims to accelerate the progress toward identifying effective therapeutic agents for Alzheimer's disease."

Takeda presentations at AAIC® 2014 are as follows:


Monday, July 14, 2014

Poster No:

P2-392

Poster Title:

Cross-Cultural Validation and Normative Study of a Neuropsychological Battery Used in the Determination of Clinical Endpoints to Delay Onset of MCI

Authors:

Kathleen A. Welsh-Bohmer, Heather R. Romero, Kathleen M. Hayden, Brenda L. Plassman, Alexandra Atkins, Adam Vaughan, Nicole Turcotte, Richard S. E. Keefe, Oksana Makeeva, Andreas U. Monsch, Giovanni B. Frisoni, Zara Melikyan, Shyama Brewster, Carl Chiang, Janet O'Neil, Jennifer Schuster, Margarita Lymboura, Grant Runyan, Mark Atkinson, Kumar Budur for the TOMMORROW Study Investigators

Location:

Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)


Tuesday, July 15, 2014

Poster No:

P3-398

Poster Title:

Deriving an Informed Neurocognitive Composite Measure for Delay of Onset Trials in Mild Cognitive Impairment due to Alzheimer's disease (MCI-AD)

Authors:

Mark Espeland, Leslie Vaughan, Heather Romero, Kathleen M. Hayden, Brenda L. Plassman, Kathleen A. Welsh-Bohmer for the TOMMORROW Study Investigators

Location:

Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)


Poster No:

P3-021

Poster Title:

Identification and Characterization of Polymorphic Structural Variants Associated with Alzheimer's Disease and Diseases of Aging

Authors:

Michael W. Lutz, Robert Saul, Daniel K. Burns, Ann M. Saunders, Allen D. Roses

Location:

Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)


Poster No:

P3-255

Poster Title:

Cultural Adaptation of Translated Neurocognitive Assessments in Russia, Switzerland and Italy: Pilot Testing for a Program to Delay the Onset of Mild Cognitive Impairment due to Alzheimer's Disease

Authors:

Alexandra S. Atkins, Richard S. E. Keefe, Adam W. Vaughan, Nicole M. Turcotte, Oksana A. Makeeva, Andreas U. Monsch, Giovanni B. Frisoni, Maura Parapini, Zara A. Melikyan, Shyama Brewster, Janet O'Neil, Jennifer Schuster, Margarita Lymboura, Heather Romero, Kathleen M. Hayden, Brenda Plassman, Kathleen A. Welsh-Bohmer

Location:

Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)


Wednesday, July 16, 2014


Session No:

FTS-03

Session Title:

The Collaboration for Alzheimer's Prevention (CAP): Advancing the Evaluation of Alzheimer's Prevention Therapies

Authors:

Kathleen A. Welsh-Bohmer, Daniel K. Burns, Stephen K. Brannan, Kumar Budur for the TOMMORROW investigators

Location:

Auditorium 15 (8:30 am - 10:00 am UTC)


Poster No:

P4-073

Poster Title:

A Pharmacogenetics Supported Clinical Trial to Delay Onset of Mild Cognitive Impairment Due to Alzheimer's Disease Using Low Dose Pioglitazone: An Update on the TOMMORROW Study

Authors:

Kumar Budur, Kathleen A. Welsh-Bohmer, Daniel K. Burns, Carl Chiang, Janet O'Neil, Grant Runyan, Marcia Cyganowski, Donna G. Crenshaw, Michael W. Lutz, Craig A. Metz, Ann M. Saunders, Deborah Yarbrough, David Yarnall, MS, Eric Lai, Stephen K. Brannan, Allen D. Roses

Location:

Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)


Poster No:

P4-284

Poster Title:

Genetic Relationship of APOE and TOMM40 Haplotypes in African American, West African, and Caucasian Cohorts

Authors:

Allen D. Roses, Michael W. Lutz, Robert Saul, Daniel K. Burns, Ann M. Saunders, Dmitry Goldgaber, Scott S. Sundseth, Patrick A. Akkari, Stephanie M. Roses, William K. Gottschalk, Keith E. Whitfield, Alexander A. Vostrov, Michael A. Hauser, R. Rand Allingham, Ornit Chiba-Falek, Kathleen A. Welsh-Bohmer

Location:

Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)


Session No:

O4-07-01

Session Title:

Effects of Pioglitazone on Mnemonic Hippocampal Function: A Pharmacologic BOLD fMRI Study in Healthy Elderly Subjects

Authors:

Stephen K. Brannan, Ahmad R. Hariri, Annchen Knodt, Adam X. Gorka, James Burke, Kathleen Welsh-Bohmer, Brenda L. Plassman, Michael Kukulka, Daniel K. Burns, Allen D. Roses

Location:

Hall C5A (4:00 pm - 5:30 pm UTC)

About the TOMMORROW Trial
The TOMMORROW trial is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The trial will use a geneticbased biomarker risk assignment algorithm comprised of apolipoprotein E (APOE) and Translocase of Outer Mitochondrial Membrane (TOMM40) genotypes and age, which is being studied to determine the risk of individuals developing mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period. Cognitively normal individuals assessed as low risk will be assigned to receive placebo. Cognitively normal individuals assessed as high-risk will be assigned to low dose pioglitazone (AD-4833 0.8 SR mg QD) or placebo. The study duration is approximately five years or the time needed to achieve 410 conversions to MCI due to AD in the high-risk group. Approximately 5,800 cognitively normal individuals aged 65-83 at 60 centers worldwide will be randomized into the study. The study will recruit internationally from large, diverse, community-based populations.

The study has two objectives:

For the genetic-based biomarker risk assignment algorithm, the primary objective is to qualify the genetic-based biomarker risk algorithm to determine the risk of developing MCI due to AD within a five year period. The primary endpoint for the genetic-based biomarker risk algorithm is time to diagnosis of MCI due to AD for placebo-treated, high-risk subjects versus placebo-treated, low-risk subjects; and to evaluate the efficacy of the investigational agent, low dose pioglitazone (AD-4833 0.8 SR mg QD) in delaying the onset of MCI due to AD in cognitively normal individuals (aged 65-83) as determined by the genetic-based biomarker risk algorithm. The primary endpoint is time to diagnosis of MCI due to AD for pioglitazone (AD-4833 0.8 SR mg QD) treated subjects versus placebo-treated subjects in the high-risk stratum.

Key secondary objectives are to evaluate the effect of low dose pioglitazone (AD-4833 0.8 SR mg QD) versus placebo on the progression of cognitive decline and to compare the effects of low dose pioglitazone (AD-4833 0.8 SR mg QD) versus placebo on functional decline and instrumental activities of daily living.

For more information on the TOMMORROW trial, please visit: www.clinicaltrials.gov.

About Alzheimer's Disease (AD)
AD is a degenerative brain disease characterized by a progressive decline in memory, thinking, comprehension, calculation, language, learning capacity and judgment sufficient to impair personal activities of daily living. Approximately 18 million Americans are currently suffering from AD, and the rate of occurrence doubles every five years for those between 65 and 85 years of age. In the 2010 World Alzheimer Report, Alzheimer's disease International estimated that there are 35.6 million people living with dementia worldwide in 2010, increasing to 65.7 million by 2030 and 115.4 million by 2050.

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

About Zinfandel Pharmaceuticals
Zinfandel Pharmaceuticals, based in Durham, N.C., is a privately held company dedicated to using pharmacogenetics to improve prediction of risk for Alzheimer's disease and thus facilitate the development of effective therapies.

SOURCE Takeda Pharmaceutical Company Limited

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES